BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDGlobeNewsWire • 05/26/26
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's DiseaseGlobeNewsWire • 05/18/26
BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology TranscriptSeeking Alpha • 05/09/26
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026GlobeNewsWire • 04/27/26
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual MeetingGlobeNewsWire • 04/14/26
BioVie Inc. (BIVI) Discusses Clinical Progress of Bezisterim Targeting Inflammation in Parkinson's, Alzheimer's, and Long COVID TranscriptSeeking Alpha • 03/05/26
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their RightsGlobeNewsWire • 02/12/26
BioVie hits enrolment milestone in early Parkinson's trial, data due later this yearProactive Investors • 01/16/26
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPRNewsWire • 12/24/25
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease TranscriptSeeking Alpha • 12/10/25